Levetiracetam oral solution is indicated for the treatment of partial-onset seizures in patients one month of age and older. It is also indicated as adjunctive therapy for myoclonic seizures in patients 12 years and older with juvenile myoclonic epilepsy, and for primary generalized tonic-clonic seizures in patients 6 years and older with idiopathic generalized epilepsy. The precise mechanism of action is unknown, but levetiracetam binds to a saturable and stereoselective neuronal binding site in rat brain tissue, thought to be the synaptic vesicle protein SV2A, involved in vesicle exocytosis. Experimental data suggests this interaction contributes to its antiseizure activity. A randomized, double-blind, positive-controlled study demonstrated that levetiracetam (1,000 mg or 5,000 mg) did not significantly prolong the QTc interval, with the upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc being below 10 milliseconds. Clinical studies, including Study 1 involving 293 patients, evaluated levetiracetam at doses of 1,000 mg or 3,000 mg daily, compared to placebo. The primary measure was the percent reduction in weekly partial seizure frequency. The results showed a 30.1% reduction in seizure frequency with 3,000 mg/day compared to 26.1% with 1,000 mg/day and 30.1% with placebo. The responder rate, representing patients with ≥50% reduction in seizure frequency, was also observed across all treatment groups. Absorption is rapid, with peak plasma concentrations occurring within an hour after oral administration. Food decreases C max by 20% and delays T max by 1.5 hours. Levetiracetam is metabolized primarily through enzymatic hydrolysis, producing a major inactive metabolite. Steady state is achieved after two days of twice-daily dosing. The plasma half-life in adults is 7 ± 1 hour. Dosage is weight-based for pediatric patients, ranging from 500 to 1,500 mg every 12 hours, adjusted based on seizure severity. Discontinuation should be avoided to minimize the risk of increased seizure frequency.